Insider Selling: TherapeuticsMD, Inc. (NASDAQ:TXMD) Director Sells 3,922 Shares of Stock

TherapeuticsMD, Inc. (NASDAQ:TXMDGet Rating) Director Gail K. Naughton sold 3,922 shares of TherapeuticsMD stock in a transaction on Wednesday, December 7th. The shares were sold at an average price of $5.26, for a total value of $20,629.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

TherapeuticsMD Stock Performance

NASDAQ:TXMD opened at $5.98 on Friday. The stock’s fifty day moving average price is $5.77 and its two-hundred day moving average price is $7.44. TherapeuticsMD, Inc. has a 1 year low of $1.99 and a 1 year high of $30.50.

TherapeuticsMD (NASDAQ:TXMDGet Rating) last issued its quarterly earnings data on Monday, November 14th. The company reported ($3.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.04) by ($1.09). The company had revenue of $20.92 million during the quarter, compared to the consensus estimate of $30.20 million. On average, analysts expect that TherapeuticsMD, Inc. will post -10.27 EPS for the current year.

Institutional Investors Weigh In On TherapeuticsMD

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Rubric Capital Management LP raised its position in shares of TherapeuticsMD by 46.1% in the third quarter. Rubric Capital Management LP now owns 1,156,953 shares of the company’s stock worth $7,682,000 after buying an additional 365,122 shares in the last quarter. Sanders Morris Harris LLC purchased a new stake in TherapeuticsMD during the third quarter valued at about $268,000. PenderFund Capital Management Ltd. purchased a new stake in TherapeuticsMD during the second quarter valued at about $313,000. Millennium Management LLC raised its position in TherapeuticsMD by 339.2% during the second quarter. Millennium Management LLC now owns 57,657 shares of the company’s stock valued at $574,000 after purchasing an additional 44,528 shares in the last quarter. Finally, UBS Group AG raised its position in TherapeuticsMD by 258.1% during the second quarter. UBS Group AG now owns 18,133 shares of the company’s stock valued at $180,000 after purchasing an additional 13,069 shares in the last quarter.

Analysts Set New Price Targets

Separately, StockNews.com began coverage on TherapeuticsMD in a research note on Wednesday, October 12th. They issued a “hold” rating on the stock.

TherapeuticsMD Company Profile

(Get Rating)

TherapeuticsMD, Inc operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system.

Featured Stories

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.